Filing Flows › ResMed (RMD) › Q4 FY26
ResMed (RMD) Q4 FY26 earnings results (fourth quarter fiscal 2026)
10-K filed Aug 13, 2026
ResMed (RMD) reported revenue of $1.5B for the fourth quarter fiscal 2026 (Q4 FY26), +9% from a year earlier and +2% from the quarter before. Operating margin was 30.7%, net earnings $383M (26.2% of revenue).
ResMed, Q4 FY26: revenue $1.5B (+9% year over year), operating margin 30.7%, net earnings $383M, operating cash flow $455M. The chart follows the revenue to costs, profit and cash.
| Q4 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.5B | +2% | +9% |
| Gross profit | $861M | -3% | +5% |
| Operating profit | $449M | -10% | -1% |
| Net earnings | $383M | -4% | +1% |
| Operating cash flow | $455M | -18% | -16% |
| Free cash flow | $404M | -22% | -21% |
What changed
Revenue was $1.5B in Q4 FY26, up 9% year over year and up 2% from the previous quarter. Sleep and Breathing Health was the largest line at 88% of revenue.
Gross margin was 58.8%, down 2.0 points from Q4 FY25. Operating profit was $0.45B, a 30.7% margin (down 3.1 points year over year). Operating profit fell $0.01B even though revenue rose $0.12B versus Q4 FY25, so costs grew faster than sales. Operating expenses grew 13% against revenue growth of 9%. The fastest-growing cost line was Research & development (+22%). Net earnings were $0.38B, up 1% year over year. The effective tax rate was 19.1%.
Operating cash flow was $0.45B (down 16% year over year), 119% of net earnings. Non-cash charges added back $0.04B of depreciation and amortization and $0.03B of share-based compensation. Capital expenditures of $0.05B left free cash flow of $0.40B.
Questions
What was ResMed's revenue in the fourth quarter fiscal 2026?
ResMed (RMD) reported revenue of $1.5B for the fourth quarter fiscal 2026 (Q4 FY26), +9% from a year earlier and +2% from the quarter before.
Was ResMed profitable in the fourth quarter fiscal 2026?
Operating profit was $449M (30.7% of revenue) and net earnings $383M.
Source: ResMed 10-K on SEC EDGAR.